BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 19472396)

  • 21. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
    Thiele J; Kvasnicka HM
    Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
    Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
    Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
    Orazi A; Germing U
    Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
    Vardiman J; Hyjek E
    Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Jak-2 positive myeloproliferative neoplasms.
    Muxí PJ; Oliver AC
    Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
    Panani AD
    Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
    Găman M; Vlădăreanu AM; Radesi S
    Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Histopathology and molecular pathology of chronic myeloproliferative disorders].
    Kreipe HH
    Veroff Pathol; 1993; 141():1-158. PubMed ID: 8372486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Malignant lymphoma and leukemia concepts in new WHO classification].
    Kikuchi M
    Rinsho Byori; 2003 Aug; 51(8):820-4. PubMed ID: 13677944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
    Spivak JL
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathology consultation on myeloproliferative neoplasms.
    Schmidt AE; Oh ST;
    Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
    Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
    Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinase drug discovery approaches in chronic myeloproliferative disorders.
    Kumar C; Purandare AV; Lee FY; Lorenzi MV
    Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
    Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
    J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.